{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T19:48:01Z","timestamp":1792784881432,"version":"4.5.0"},"reference-count":48,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T00:00:00Z","timestamp":1791936000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T00:00:00Z","timestamp":1791936000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/100000054","name":"U.S. Department of Health & Human Services | NIH | National Cancer Institute","doi-asserted-by":"publisher","award":["R01CA228457"],"award-info":[{"award-number":["R01CA228457"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Fox Chase Cancer Center Institute for Cancer Research","id":[{"id":"https:\/\/ror.org\/0567t7073","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Leukemia"],"DOI":"10.1038\/s41375-026-03169-w","type":"journal-article","created":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T00:07:10Z","timestamp":1792022830000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Neoantigenic receptor ROR1 promotes cell growth through diverse and complementary mechanisms"],"prefix":"10.1038","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2296-1577","authenticated-orcid":false,"given":"Shengchun","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shilpa","family":"Rao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1329-2113","authenticated-orcid":false,"given":"Cosimo","family":"Lobello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Rushmore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bhaumik","family":"Shah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suzanne","family":"Paley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4036-3899","authenticated-orcid":false,"given":"Pradeep","family":"Gupta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Kalgren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dinesh","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neil V.","family":"Sen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katrin","family":"Kurz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8172-1042","authenticated-orcid":false,"given":"Phassawan","family":"Rungsiprakarn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nashwa","family":"Mansoor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brigitte","family":"Dade","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashishkumar","family":"Sonani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vanessa","family":"Dupoux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K. Qi","family":"Cai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas","family":"Mackrides","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1853-9253","authenticated-orcid":false,"given":"Donald","family":"Baldwin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter D.","family":"Karp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mowafaq","family":"Jillab","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7990-6793","authenticated-orcid":false,"given":"German","family":"Ott","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reza","family":"Nejati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kavindra","family":"Nath","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-0907-3541","authenticated-orcid":false,"given":"Johnvesly","family":"Basappa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1988-3670","authenticated-orcid":false,"given":"Mariusz A.","family":"Wasik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,10,14]]},"reference":[{"key":"3169_CR1","doi-asserted-by":"publisher","first-page":"1583","DOI":"10.1182\/blood.2021014760","volume":"140","author":"TJ Kipps","year":"2022","unstructured":"Kipps TJ. ROR1: an orphan becomes apparent. Blood. 2022;140:1583\u201391.","journal-title":"Blood"},{"key":"3169_CR2","doi-asserted-by":"crossref","unstructured":"Raso MG, Barrientos Toro E, Evans K, Rizvi Y, Lazcano R, Akcakanat A, et al. Heterogeneous profile of ROR1 protein expression across tumor types. Cancers (Basel). 2024;16(10):1874.","DOI":"10.3390\/cancers16101874"},{"key":"3169_CR3","doi-asserted-by":"publisher","DOI":"10.1038\/srep05811","volume":"4","author":"H Zhang","year":"2014","unstructured":"Zhang H, Qiu J, Ye C, Yang D, Gao L, Su Y, et al. ROR1 expression correlated with poor clinical outcome in human ovarian cancer. Sci Rep. 2014;4:5811.","journal-title":"Sci Rep"},{"key":"3169_CR4","doi-asserted-by":"publisher","first-page":"2931","DOI":"10.1182\/blood-2016-04-712562","volume":"128","author":"B Cui","year":"2016","unstructured":"Cui B, Ghia EM, Chen L, Rassenti LZ, DeBoever C, Widhopf GF 2nd, et al. High-level ROR1 associates with accelerated disease progression in chronic lymphocytic leukemia. Blood. 2016;128:2931\u201340.","journal-title":"Blood"},{"key":"3169_CR5","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2024.1383741","volume":"14","author":"MA Wasik","year":"2024","unstructured":"Wasik MA, Kim PM, Nejati R. Diverse and reprogrammable mechanisms of malignant cell transformation in lymphocytes: pathogenetic insights and translational implications. Front Oncol. 2024;14:1383741.","journal-title":"Front Oncol"},{"key":"3169_CR6","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2020.103212","volume":"158","author":"N Monga","year":"2021","unstructured":"Monga N, Tam C, Garside J, Davids MS, Ward K, Quigley J, et al. Clinical efficacy and safety of first-line treatments in patients with mantle cell lymphoma: a systematic literature review. Crit Rev Oncol Hematol. 2021;158:103212.","journal-title":"Crit Rev Oncol Hematol"},{"key":"3169_CR7","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/10428194.2023.2264430","volume":"65","author":"C Gribbin","year":"2024","unstructured":"Gribbin C, Chen J, Martin P, Ruan J. Novel treatment for mantle cell lymphoma - impact of BTK inhibitors and beyond. Leuk Lymphoma. 2024;65:1\u201313.","journal-title":"Leuk Lymphoma"},{"key":"3169_CR8","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1182\/blood.2023022352","volume":"145","author":"CE Ryan","year":"2025","unstructured":"Ryan CE, Armand P, LaCasce AS. Frontline management of mantle cell lymphoma. Blood. 2025;145:663\u201372.","journal-title":"Blood"},{"key":"3169_CR9","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1182\/blood.2023022353","volume":"145","author":"E Silkenstedt","year":"2025","unstructured":"Silkenstedt E, Dreyling M. Treatment of relapsed\/refractory MCL. Blood. 2025;145:673\u201382.","journal-title":"Blood"},{"key":"3169_CR10","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1182\/blood.2023022354","volume":"145","author":"P Jain","year":"2025","unstructured":"Jain P, Wang M. High-risk MCL: recognition and treatment. Blood. 2025;145:683\u201395.","journal-title":"Blood"},{"key":"3169_CR11","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1016\/S1470-2045(24)00682-X","volume":"26","author":"M Wang","year":"2025","unstructured":"Wang M, Jurczak W, Trneny M, Belada D, Wrobel T, Ghosh N, et al. Ibrutinib plus venetoclax in relapsed or refractory mantle cell lymphoma (SYMPATICO): a multicentre, randomised, double-blind, placebo-controlled, phase 3 study. Lancet Oncol. 2025;26:200\u201313.","journal-title":"Lancet Oncol"},{"key":"3169_CR12","doi-asserted-by":"publisher","first-page":"2276","DOI":"10.1200\/JCO-25-00690","volume":"43","author":"M Wang","year":"2025","unstructured":"Wang M, Salek D, Belada D, Song Y, Jurczak W, Kahl BS, et al. Acalabrutinib plus bendamustine-rituximab in untreated mantle cell lymphoma. J Clin Oncol. 2025;43:2276\u201384.","journal-title":"J Clin Oncol"},{"key":"3169_CR13","doi-asserted-by":"publisher","first-page":"1099","DOI":"10.1182\/blood.2020006783","volume":"138","author":"DM Stephens","year":"2021","unstructured":"Stephens DM, Byrd JC. Resistance to Bruton tyrosine kinase inhibitors: the Achilles heel of their success story in lymphoid malignancies. Blood. 2021;138:1099\u2013109.","journal-title":"Blood"},{"key":"3169_CR14","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1111\/bjh.18418","volume":"200","author":"S Nakhoda","year":"2023","unstructured":"Nakhoda S, Vistarop A, Wang YL. Resistance to Bruton tyrosine kinase inhibition in chronic lymphocytic leukaemia and non-Hodgkin lymphoma. Br J Haematol. 2023;200:137\u201349.","journal-title":"Br J Haematol"},{"key":"3169_CR15","doi-asserted-by":"publisher","first-page":"2794","DOI":"10.1182\/bloodadvances.2022008821","volume":"7","author":"S Bonfiglio","year":"2023","unstructured":"Bonfiglio S, Sutton LA, Ljungstr\u00f6m V, Capasso A, Pandzic T, Westr\u00f6m S, et al. BTK and PLCG2 remain unmutated in one-third of patients with CLL relapsing on ibrutinib. Blood Adv. 2023;7:2794\u2013806.","journal-title":"Blood Adv"},{"key":"3169_CR16","doi-asserted-by":"publisher","DOI":"10.1186\/s12967-024-05371-9","volume":"22","author":"K Nath","year":"2024","unstructured":"Nath K, Gupta PK, Basappa J, Wang S, Sen N, Lobello C, et al. Impact of therapeutic inhibition of oncogenic cell signaling tyrosine kinase on cell metabolism: in vivo-detectable metabolic biomarkers of inhibition. J Transl Med. 2024;22:622.","journal-title":"J Transl Med"},{"key":"3169_CR17","doi-asserted-by":"publisher","first-page":"2043","DOI":"10.4049\/jimmunol.1801327","volume":"203","author":"Q Zhang","year":"2019","unstructured":"Zhang Q, Wang HY, Liu X, Nunez-Cruz S, Jillab M, Melnikov O, et al. Cutting Edge: ROR1\/CD19 receptor complex promotes growth of mantle cell lymphoma cells independently of the B cell receptor-BTK signaling pathway. J Immunol. 2019;203:2043\u20138.","journal-title":"J Immunol"},{"key":"3169_CR18","doi-asserted-by":"publisher","first-page":"1365","DOI":"10.1158\/1541-7786.MCR-18-0256","volume":"17","author":"SC Lee","year":"2019","unstructured":"Lee SC, Shestov AA, Guo L, Zhang Q, Roman JC, Liu X, et al. Metabolic detection of Bruton\u2019s tyrosine kinase inhibition in mantle cell lymphoma cells. Mol Cancer Res. 2019;17:1365\u201377.","journal-title":"Mol Cancer Res"},{"key":"3169_CR19","doi-asserted-by":"publisher","first-page":"568","DOI":"10.3389\/fonc.2019.00568","volume":"9","author":"Q Zhang","year":"2019","unstructured":"Zhang Q, Wang HY, Liu X, Roth MH, Shestov AA, Lee SC, et al. Dynamic changes in gene mutational landscape with preservation of core mutations in mantle cell lymphoma cells. Front Oncol. 2019;9:568.","journal-title":"Front Oncol"},{"key":"3169_CR20","doi-asserted-by":"publisher","first-page":"1980","DOI":"10.1182\/blood.2020005123","volume":"136","author":"Q Zhang","year":"2020","unstructured":"Zhang Q, Orlando EJ, Wang HY, Bogusz AM, Liu X, Lacey SF, et al. Transdifferentiation of lymphoma into sarcoma associated with profound reprogramming of the epigenome. Blood. 2020;136:1980\u20133.","journal-title":"Blood"},{"key":"3169_CR21","doi-asserted-by":"publisher","first-page":"2436","DOI":"10.1038\/s41375-023-02038-0","volume":"37","author":"Q Zhang","year":"2023","unstructured":"Zhang Q, Basappa J, Wang HY, Nunez-Cruz S, Lobello C, Wang S, et al. Chimeric kinase ALK induces expression of NAMPT and selectively depends on this metabolic enzyme to sustain its own oncogenic function. Leukemia. 2023;37:2436\u201347.","journal-title":"Leukemia"},{"key":"3169_CR22","doi-asserted-by":"publisher","first-page":"3061","DOI":"10.1158\/1078-0432.CCR-16-2083","volume":"23","author":"A Balakrishnan","year":"2017","unstructured":"Balakrishnan A, Goodpaster T, Randolph-Habecker J, Hoffstrom BG, Jalikis FG, Koch LK, et al. Analysis of ROR1 protein expression in human cancer and normal tissues. Clin Cancer Res. 2017;23:3061\u201371.","journal-title":"Clin Cancer Res"},{"key":"3169_CR23","doi-asserted-by":"publisher","DOI":"10.1186\/s12859-016-1382-1","volume":"17","author":"S Paley","year":"2016","unstructured":"Paley S, O\u2019Maille PE, Weaver D, Karp PD. Pathway collages: personalized multi-pathway diagrams. BMC Bioinformatics. 2016;17:529.","journal-title":"BMC Bioinformatics"},{"key":"3169_CR24","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/j.exphem.2023.05.002","volume":"123","author":"KE Wilcher","year":"2023","unstructured":"Wilcher KE, Page ERH, Privette Vinnedge LM. The impact of the chromatin binding DEK protein in hematopoiesis and acute myeloid leukemia. Exp Hematol. 2023;123:18\u201327.","journal-title":"Exp Hematol"},{"key":"3169_CR25","doi-asserted-by":"crossref","unstructured":"Johnstone ME, Leck AL, Lange TE, Wilcher KE, Shephard MS, Paranjpe A, et al. DEK promotes mammary hyperplasia and is associated with H3K27me3 epigenetic modifications. Life Sci Alliance. 2025;8(9):e202503230.","DOI":"10.26508\/lsa.202503230"},{"key":"3169_CR26","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.680834","volume":"11","author":"Y Zhao","year":"2021","unstructured":"Zhao Y, Zhang D, Guo Y, Lu B, Zhao ZJ, Xu X, et al. Tyrosine kinase ROR1 as a target for anti-cancer therapies. Front Oncol. 2021;11:680834.","journal-title":"Front Oncol"},{"key":"3169_CR27","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1038\/s41420-024-02239-1","volume":"10","author":"AB Tigu","year":"2024","unstructured":"Tigu AB, Munteanu R, Moldovan C, Rares D, Kegyes D, Tomai R, et al. Therapeutic advances in the targeting of ROR1 in hematological cancers. Cell Death Discov. 2024;10:471.","journal-title":"Cell Death Discov"},{"key":"3169_CR28","doi-asserted-by":"publisher","first-page":"2291","DOI":"10.1038\/s41375-018-0113-1","volume":"32","author":"M Hojjat-Farsangi","year":"2018","unstructured":"Hojjat-Farsangi M, Daneshmanesh AH, Khan AS, Shetye J, Mozaffari F, Kharaziha P, et al. First-in-class oral small molecule inhibitor of the tyrosine kinase ROR1 (KAN0439834) induced significant apoptosis of chronic lymphocytic leukemia cells. Leukemia. 2018;32:2291\u20135.","journal-title":"Leukemia"},{"key":"3169_CR29","doi-asserted-by":"crossref","unstructured":"Ghaderi A, Zhong W, Okhovat MA, Aschan J, Svensson A, Sander B, et al. A ROR1 small molecule inhibitor (KAN0441571C) induced significant apoptosis of mantle cell lymphoma (MCL) cells. Pharmaceutics. 2022;14(10):2238.","DOI":"10.3390\/pharmaceutics14102238"},{"key":"3169_CR30","doi-asserted-by":"crossref","unstructured":"Smaldone G, Miranda MR, Di Matteo F, Napolitano V, Aliberti M, Musella S, et al. Novel para-phenylenediamine-based derivatives as receptor tyrosine kinase-like orphan receptor 1 (ROR1) inhibitors: an in vitro preliminary characterization. ChemMedChem. 2025;20(14):e202500247.","DOI":"10.1002\/cmdc.202500247"},{"key":"3169_CR31","doi-asserted-by":"publisher","first-page":"16138","DOI":"10.1021\/acs.jmedchem.5c01080","volume":"68","author":"D Lu","year":"2025","unstructured":"Lu D, Lyu W, Chi X, Li Q, Zhou Y, Lu B, et al. Structure-based discovery of quinazolin-2-amine derivatives as potent ROR1 pseudokinase inhibitors with in vitro and in vivo efficacy against triple-negative breast cancer. J Med Chem. 2025;68:16138\u201371.","journal-title":"J Med Chem"},{"key":"3169_CR32","doi-asserted-by":"publisher","first-page":"11188","DOI":"10.1021\/acs.jmedchem.5c00189","volume":"68","author":"Q Zheng","year":"2025","unstructured":"Zheng Q, Qiu X, Luo D, Ma H, Ming Y, Pu W, et al. Optimization of 1-Methyl-3-(pyridin-3-yl)-1H-indol derivatives as ROR1 inhibitors with improved activity and selectivity. J Med Chem. 2025;68:11188\u2013216.","journal-title":"J Med Chem"},{"key":"3169_CR33","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmech.2025.117325","volume":"286","author":"J Li","year":"2025","unstructured":"Li J, Li L, Hou C, Tian Z, Zhou Y, Zhang J, et al. Discovery of the first potent ROR1 degrader for the treatment of non-small cell lung cancer. Eur J Med Chem. 2025;286:117325.","journal-title":"Eur J Med Chem"},{"key":"3169_CR34","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijbiomac.2025.145700","volume":"319","author":"Y Zhao","year":"2025","unstructured":"Zhao Y, Wang H, Wu P, Zhang Y, Wang Z, Xu W. Development of nanobody-based PROTAC (NbTAC) for ROR1 degradation by RNF149. Int J Biol Macromol. 2025;319:145700.","journal-title":"Int J Biol Macromol"},{"key":"3169_CR35","doi-asserted-by":"publisher","first-page":"E5467","DOI":"10.1073\/pnas.1719905115","volume":"115","author":"J Qi","year":"2018","unstructured":"Qi J, Li X, Peng H, Cook EM, Dadashian EL, Wiestner A, et al. Potent and selective antitumor activity of a T cell-engaging bispecific antibody targeting a membrane-proximal epitope of ROR1. Proc Natl Acad Sci USA. 2018;115:E5467\u201376.","journal-title":"Proc Natl Acad Sci USA"},{"key":"3169_CR36","doi-asserted-by":"publisher","first-page":"3365","DOI":"10.1182\/blood.2020008404","volume":"137","author":"T Vaisitti","year":"2021","unstructured":"Vaisitti T, Arruga F, Vitale N, Lee TT, Ko M, Chadburn A, et al. ROR1 targeting with the antibody-drug conjugate VLS-101 is effective in Richter syndrome patient-derived xenograft mouse models. Blood. 2021;137:3365\u201377.","journal-title":"Blood"},{"key":"3169_CR37","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1186\/s13045-021-01143-w","volume":"14","author":"VC Jiang","year":"2021","unstructured":"Jiang VC, Liu Y, Jordan A, McIntosh J, Li Y, Che Y, et al. The antibody drug conjugate VLS-101 targeting ROR1 is effective in CAR T-resistant mantle cell lymphoma. J Hematol Oncol. 2021;14:132.","journal-title":"J Hematol Oncol"},{"key":"3169_CR38","doi-asserted-by":"publisher","first-page":"1116","DOI":"10.1097\/01.HS9.0000847788.96420.63","volume":"6","author":"M Wang","year":"2022","unstructured":"Wang M, Mei M, Barr PM, Barrientos J, de Vos S, Furman R, et al. P1231: Zilovertamab vedotin (MK-2140) for the treatment of Non-Hodgkin lymphoma: the phase 1 dose escalation and cohort expansion waveline-001 study of an anti-rorl antibody-drug conjugate. Hemasphere. 2022;6:1116.","journal-title":"Hemasphere"},{"key":"3169_CR39","doi-asserted-by":"publisher","first-page":"EVIDoa2100001","DOI":"10.1056\/EVIDoa2100001","volume":"1","author":"ML Wang","year":"2022","unstructured":"Wang ML, Barrientos JC, Furman RR, Mei M, Barr PM, Choi MY, et al. Zilovertamab vedotin targeting of ROR1 as therapy for lymphoid cancers. NEJM Evid. 2022;1:EVIDoa2100001.","journal-title":"NEJM Evid"},{"key":"3169_CR40","doi-asserted-by":"publisher","first-page":"4532","DOI":"10.1182\/blood-2010-05-283309","volume":"116","author":"M Hudecek","year":"2010","unstructured":"Hudecek M, Schmitt TM, Baskar S, Lupo-Stanghellini MT, Nishida T, Yamamoto TN, et al. The B-cell tumor-associated antigen ROR1 can be targeted with T cells modified to express a ROR1-specific chimeric antigen receptor. Blood. 2010;116:4532\u201341.","journal-title":"Blood"},{"key":"3169_CR41","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1158\/2326-6066.CIR-14-0163","volume":"3","author":"C Berger","year":"2015","unstructured":"Berger C, Sommermeyer D, Hudecek M, Berger M, Balakrishnan A, Paszkiewicz PJ, et al. Safety of targeting ROR1 in primates with chimeric antigen receptor-modified T cells. Cancer Immunol Res. 2015;3:206\u201316.","journal-title":"Cancer Immunol Res"},{"key":"3169_CR42","doi-asserted-by":"publisher","first-page":"4104","DOI":"10.1038\/s41388-022-02416-5","volume":"41","author":"H Peng","year":"2022","unstructured":"Peng H, Nerreter T, Mestermann K, Wachter J, Chang J, Hudecek M, et al. ROR1-targeting switchable CAR-T cells for cancer therapy. Oncogene. 2022;41:4104\u201314.","journal-title":"Oncogene"},{"key":"3169_CR43","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1016\/j.ccell.2019.02.003","volume":"35","author":"S Srivastava","year":"2019","unstructured":"Srivastava S, Salter AI, Liggitt D, Yechan-Gunja S, Sarvothama M, Cooper K, et al. Logic-gated ROR1 chimeric antigen receptor expression rescues T cell-mediated toxicity to normal tissues and enables selective tumor targeting. Cancer Cell. 2019;35:489\u2013503.e8.","journal-title":"Cancer Cell"},{"key":"3169_CR44","first-page":"A318","volume":"11","author":"VC Lam","year":"2023","unstructured":"Lam VC, Li A, Casas MG, Barragan J, Cheung C, Briones J, et al. 278 Preclinical development of LYL119, a ROR1-targeted CAR T-cell product incorporating four novel T-cell reprogramming technologies to overcome barriers to effective cell therapy for solid tumors. J Immunother Cancer. 2023;11:A318\u20139.","journal-title":"J Immunother Cancer"},{"key":"3169_CR45","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2023.1121020","volume":"10","author":"DA Osorio-Rodr\u00edguez","year":"2023","unstructured":"Osorio-Rodr\u00edguez DA, Camacho BA, Ram\u00edrez-Segura C. Anti-ROR1 CAR-T cells: architecture and performance. Front Med (Lausanne). 2023;10:1121020.","journal-title":"Front Med (Lausanne)"},{"key":"3169_CR46","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1158\/1078-0432.CCR-24-2172","volume":"31","author":"CA Jaeger-Ruckstuhl","year":"2025","unstructured":"Jaeger-Ruckstuhl CA, Specht JM, Voutsinas JM, MacMillan HR, Wu QV, Muhunthan V, et al. Phase I study of ROR1-specific CAR-T cells in advanced hematopoietic and epithelial malignancies. Clin Cancer Res. 2025;31:503\u201314.","journal-title":"Clin Cancer Res"},{"key":"3169_CR47","doi-asserted-by":"publisher","DOI":"10.1016\/j.cellsig.2023.110588","volume":"104","author":"MJ Quezada","year":"2023","unstructured":"Quezada MJ, Lopez-Bergami P. The signaling pathways activated by ROR1 in cancer. Cell Signal. 2023;104:110588.","journal-title":"Cell Signal"},{"key":"3169_CR48","doi-asserted-by":"publisher","DOI":"10.1016\/j.exphem.2024.104693","volume":"142","author":"T Yabushita","year":"2025","unstructured":"Yabushita T, Goyama S. Nucleic acid metabolism: the key therapeutic target for myeloid tumors. Exp Hematol. 2025;142:104693.","journal-title":"Exp Hematol"}],"container-title":["Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41375-026-03169-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41375-026-03169-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41375-026-03169-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T00:07:12Z","timestamp":1792022832000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41375-026-03169-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,14]]},"references-count":48,"alternative-id":["3169"],"URL":"https:\/\/doi.org\/10.1038\/s41375-026-03169-w","relation":{},"ISSN":["0887-6924","1476-5551"],"issn-type":[{"value":"0887-6924","type":"print"},{"value":"1476-5551","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,14]]},"assertion":[{"value":"23 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 September 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 September 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 October 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}}]}}